구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AA (Abiraterone acetate, Abiraterone acetate (AA)) Janssen Research & Development, LL…·Metastatic Castration-sensitive Pr… 178 trials·t½ 3.2 h |
|---|---|
Overview Program | Abiraterone acetate (AA) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Metastatic Castration-sensitive Prostate |
Overview Indication | Metastatic Castration-sensitive Prostate Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapies |
MoA Mechanism | targets, and regulatory pathway |
MoA Biomarker | biomarker source |
PK/PD Half-life | 3.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | ASPIS Academy: A blueprint for building early-career researcher networks to advance NAM-based risk assessment.. Chemical risk assessment is moving away from traditional animal-based testing toward New Approach Methodologies (NAMs) that are more human-relevant, efficient, and aligned with the replacement, reduction, and refinement of animal use. This transition depends not only on new methods and t… |
Toxicology CRS | Reported |
Clinical Safety signal | ASPIS Academy: A blueprint for building early-career researcher networks to advance NAM-based risk assessment.. Chemical risk assessment is moving away from traditional animal-based testing toward New Approach Methodologies (NAMs) that are more human-relevant, efficient, and aligned with the replacement, reduction, and refinement of animal use. This transition depends not only on new methods and t… |
Clinical Selected reported efficacy | 100% |
Clinical Reported OS | 20.6 |
Clinical Result source | ClinicalTrials.gov NCT05520138 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05520138 |
Preclinical Animal (cat.) | Rat |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | AA (Abiraterone acetate, Abiraterone acetate (AA)) Janssen Research & Development, LL…·Metastatic Castration-sensitive Pr… 178 trials·t½ 3.2 h |
|---|---|
Overview Program | Abiraterone acetate (AA) |
Overview Company | Janssen Research & Development, LLC |
Overview Modality | CGT |
Overview Target | Metastatic Castration-sensitive Prostate |
Overview Indication | Metastatic Castration-sensitive Prostate Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Standard Database |
Overview Data Confidence | Data Confidence · Medium |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Technology Vector | retroviral therapies |
MoA Mechanism | targets, and regulatory pathway |
MoA Biomarker | biomarker source |
PK/PD Half-life | 3.2 h |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Human, Mouse, In vitro |
PK/PD Experiment | biodistribution |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Human, Mouse |
Toxicology Major finding | ASPIS Academy: A blueprint for building early-career researcher networks to advance NAM-based risk assessment.. Chemical risk assessment is moving away from traditional animal-based testing toward New Approach Methodologies (NAMs) that are more human-relevant, efficient, and aligned with the replacement, reduction, and refinement of animal use. This transition depends not only on new methods and t… |
Toxicology CRS | Reported |
Clinical Safety signal | ASPIS Academy: A blueprint for building early-career researcher networks to advance NAM-based risk assessment.. Chemical risk assessment is moving away from traditional animal-based testing toward New Approach Methodologies (NAMs) that are more human-relevant, efficient, and aligned with the replacement, reduction, and refinement of animal use. This transition depends not only on new methods and t… |
Clinical Selected reported efficacy | 100% |
Clinical Reported OS | 20.6 |
Clinical Result source | ClinicalTrials.gov NCT05520138 |
Clinical Program phase | PHASE_3 |
Clinical Trial activity | No active/completed counts |
Clinical Trial ref | NCT05520138 |
Preclinical Animal (cat.) | Rat |
추천 비교
추천 비교